Samsung Biologics Achieves Leadership in Water Security Management and Sustainability Efforts
On February 12, 2025, Samsung Biologics (KRX: 207940.KS), a prominent global contract development and manufacturing organization (CDMO), announced a significant achievement in its sustainability efforts by receiving 'Leadership' status and an A- rating from the Carbon Disclosures Project (CDP) for its water security management. Recognized for its commitment to efficient water resource management, Samsung Biologics participated in this evaluation category for the first time, indicating a strong entry into sustainable practices.
The rating from CDP, a respected non-profit organization assessing environmental transparency and performance across over 24,800 global companies, underscores Samsung Biologics' dedication to implementing effective environmental, social, and governance (ESG) strategies. The company is deeply committed to enhancing resilience and managing both water pollution and consumption effectively.
John Rim, the CEO and President of Samsung Biologics, emphasized the company's ongoing mission to integrate ESG principles into all aspects of its operations. "As a sustainable CDMO, we are continuously striving to incorporate ESG principles into our operations to help achieve our net zero transition and provide more sustainable services," Rim stated. In collaboration with leading global pharmaceutical companies, Samsung Biologics aims to encourage its suppliers to develop sustainable supply chains and to foster meaningful changes across the healthcare industry.
To illustrate its commitment to sustainability, Samsung Biologics has signed renewable Power Purchase Agreements (PPAs) and is set to enhance its water resource management strategies. The company also aims to proactively identify risks across its operations to reduce environmental impacts. By leading initiatives within the Supply Chains Working Group of the Sustainable Markets Initiative (SMI) Health Systems Task Force, the organization collaborates with various stakeholders, including other global pharmaceutical firms and both public and private sectors, to advance towards a healthier and sustainable future.
Samsung Biologics is accelerating its shift towards renewable energy via PPAs and is committed to improving product carbon footprint assessments in its quest to reach a net-zero status by 2050. Efforts to reduce emissions include implementing low-carbon technologies such as high-efficiency boilers, solar panel installations across facilities, and energy monitoring systems. The CDMO is equally focused on enhancing water-use efficiency, crucial for sustainable operation.
Incorporated to meet diverse client needs, Samsung Biologics offers fully integrated CDMO services, which encompass full development and manufacturing solutions—starting from cell line development to final aseptic filling and laboratory testing for biopharmaceutical products. The company’s advanced facilities comply with CGMP standards, featuring bioreactors of various sizes to accommodate differing client requirements—totaling a capacity of 604 kL at their Bio Campus I, with the upcoming Bio Campus II projected to operationalize in April 2025, adding 180 kL of biomanufacturing capacity.
Additionally, establishing Samsung Biologics America has allowed the company to enhance collaboration with clients throughout the U.S. and Europe, thereby strengthening its operational footprint. In alignment with their sustainability goals, investments in capabilities such as antibody-drug conjugates (ADC) facilities, mRNA technologies, and expanded aseptic filling capacity are being prioritized. By adhering to timelines and delivering comprehensive solutions, Samsung Biologics establishes itself as the preferred sustainable CDMO partner, committed to operational excellence and flexibility in meeting client demands.
Ultimately, the recognition from CDP not only highlights Samsung Biologics' leadership in water management but also showcases its unwavering commitment to sustainability, a critical aspect in today’s biopharmaceutical landscape. As global attention towards environmental issues increases, Samsung Biologics is well-positioned to lead the change as a proactive, responsible player in the industry.
The rating from CDP, a respected non-profit organization assessing environmental transparency and performance across over 24,800 global companies, underscores Samsung Biologics' dedication to implementing effective environmental, social, and governance (ESG) strategies. The company is deeply committed to enhancing resilience and managing both water pollution and consumption effectively.
John Rim, the CEO and President of Samsung Biologics, emphasized the company's ongoing mission to integrate ESG principles into all aspects of its operations. "As a sustainable CDMO, we are continuously striving to incorporate ESG principles into our operations to help achieve our net zero transition and provide more sustainable services," Rim stated. In collaboration with leading global pharmaceutical companies, Samsung Biologics aims to encourage its suppliers to develop sustainable supply chains and to foster meaningful changes across the healthcare industry.
To illustrate its commitment to sustainability, Samsung Biologics has signed renewable Power Purchase Agreements (PPAs) and is set to enhance its water resource management strategies. The company also aims to proactively identify risks across its operations to reduce environmental impacts. By leading initiatives within the Supply Chains Working Group of the Sustainable Markets Initiative (SMI) Health Systems Task Force, the organization collaborates with various stakeholders, including other global pharmaceutical firms and both public and private sectors, to advance towards a healthier and sustainable future.
Samsung Biologics is accelerating its shift towards renewable energy via PPAs and is committed to improving product carbon footprint assessments in its quest to reach a net-zero status by 2050. Efforts to reduce emissions include implementing low-carbon technologies such as high-efficiency boilers, solar panel installations across facilities, and energy monitoring systems. The CDMO is equally focused on enhancing water-use efficiency, crucial for sustainable operation.
Incorporated to meet diverse client needs, Samsung Biologics offers fully integrated CDMO services, which encompass full development and manufacturing solutions—starting from cell line development to final aseptic filling and laboratory testing for biopharmaceutical products. The company’s advanced facilities comply with CGMP standards, featuring bioreactors of various sizes to accommodate differing client requirements—totaling a capacity of 604 kL at their Bio Campus I, with the upcoming Bio Campus II projected to operationalize in April 2025, adding 180 kL of biomanufacturing capacity.
Additionally, establishing Samsung Biologics America has allowed the company to enhance collaboration with clients throughout the U.S. and Europe, thereby strengthening its operational footprint. In alignment with their sustainability goals, investments in capabilities such as antibody-drug conjugates (ADC) facilities, mRNA technologies, and expanded aseptic filling capacity are being prioritized. By adhering to timelines and delivering comprehensive solutions, Samsung Biologics establishes itself as the preferred sustainable CDMO partner, committed to operational excellence and flexibility in meeting client demands.
Ultimately, the recognition from CDP not only highlights Samsung Biologics' leadership in water management but also showcases its unwavering commitment to sustainability, a critical aspect in today’s biopharmaceutical landscape. As global attention towards environmental issues increases, Samsung Biologics is well-positioned to lead the change as a proactive, responsible player in the industry.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.